Shifting their focus to metastatic bladder cancer, the Oncology Brothers and Rana McKay, MD, reflect on data from EV-302 and consider how enfortumab vedotin + pembrolizumab has shifted the treatment landscape.
New Study Shows Disparity in Prostate Cancer Treatment and Survival
A new study found that Black patients with prostate cancer were less likely to get new treatments and had a higher risk of death than White patients.
Read More
Dizman’s Global Pursuit to Cancer Research and Understanding
In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.
Listen
NCCN Recommends First AI Prognostic Tool in Prostate Cancer
The National Comprehensive Cancer Network has included ArteraAI in its clinical practice guidelines as a predictive test for localized prostate cancer.
A Deep Dive Into the Evolving Landscape of Prostate Cancer
In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.
Subcutaneous Nivolumab Delivers Clinical Equipoise to Standard IV Dosing in ccRCC
Subcutaneous nivolumab coformulated with rHuPH20 showed noninferiority of PK exposures compared with intravenous nivolumab in metastatic ccRCC.
Adjuvant Pembrolizumab Notably Improves OS vs Placebo in ccRCC
Adjuvant pembrolizumab treatment significantly improved overall survival vs placebo in patients with clear cell renal cell carcinoma.